Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTER-EWING-1 Trial 1 in newly diagnosed Ewing sarcoma
ISRCTN17938906Phase 3Recruiting
- Sponsor
- University of Birmingham
- Start
- Apr 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of vinorelbine and cyclophosphamide in Ewing sarcoma and round cell sarcoma (6 arms), sponsored by University of Birmingham. Primary endpoint: Event-free survival. Started Apr 2023; status: recruiting.
02
Drugs
vinorelbinecyclophosphamide
03
Conditions
Ewing sarcomaround cell sarcoma
Beyond the preview
Go deeper on ISRCTN17938906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17938906.